Allergy Therapeutics plc
("Allergy Therapeutics" or the "Group")
Trading Update
15% constant currency revenue growth
Double-digit compound annual revenue growth over the past 18 years
18 July 2017 Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group
specialising in allergy vaccines, today provides a trading update for the year ended 30 June 2017 ahead of its Preliminary Results
to be announced in September 2017.
Financials
Revenues for the year are expected to be ahead of market expectations at £64.1m (2016: £48.5m). This strong
performance represents 15% annual growth on a constant currency basis and 32% on a reported basis which reflects the favourable
euro exchange rate. The Company is continuing to gain market share within its core markets in Europe. Revenues have grown over the
past 18 years at a double-digit compound annual growth rate. Research and development expenditure for the 2017 financial year is
anticipated to be lower than market expectations due to the phasing of activities across the year end and these costs will now be
incurred in financial year 2018. The ongoing pipeline trials continue to progress well and timing remains in line with Board
expectations.
The cash balance at the end of June 2017 was £22.1m (30 June 2016: £23.4m).
Products
Allergy Therapeutics' market penetration has continued with strong growth in Pollinex Quattro and Pollinex.
Venomil sales have also performed well due to the pre-stocking of raw materials compared to elsewhere in the market where there
have been shortages of stock. Sales of the newer products in the Group's portfolio (Synbiotics and Acarovac) continue to develop
well.
Pipeline
In Europe, recruitment of patients for the pivotal Phase III PQ Birch trial is on track with the trial still
expected to start in the autumn of 2017. Likewise for the US, the Phase II Grass MATA MPL trial is also still planned to start this
autumn. Patients for the Acarovac Quattro Phase I trial are being recruited and results continue to be expected in the autumn of
2018.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "Revenue growth
of 15% at constant currency reflects the continued strong performance of the product portfolio and its growing market share. Our
successful strategy focuses on our patient-convenient products and controlled investment in our development pipeline to expand our
addressable market. Our double digit CAGR of revenue over the past 18 years demonstrates that we have a robust, reliable and
successful business model."
This announcement contains insider information for the purposes of Article 7 of Regulatory (EU)
No596/2014.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Finance Director
Panmure Gordon
+44 (0) 20 7886 2500
Freddy Crossley / Duncan Monteith, Corporate Finance
Tom Salvesen, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / Ivar Milligan / Philippa Gardner
allergytherapeutics@consilium-comms.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic
disorders including immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary products and third
party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten
countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut
allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in
development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than
11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group employs c.500
employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.
